

Original Research Article

Antioxidant and hepatoprotective activity of methanolic extract of *Cassia sieberiana* leaves in carbon tetrachloride-induced hepatotoxicity in rats

Abstract

Cassia sieberiana (Fabaceae) commonly called “drumstick” is a perennial plant that grows up to 10-20 m high with drooping branches and bright yellow flowers. The present study was aimed at evaluating the hepatoprotective and antioxidant activity of the methanolic extract of *C. sieberiana* leaves. The hepatoprotective activity of *C. sieberiana* was evaluated using carbon tetrachloride (CCl₄) induced hepatotoxicity in albino rats. The antioxidant activity was determined using both *in vitro* (2, 2-diphenyl-1-picrylhydrazine photometric assay) and *in vivo* (malondialdehyde and catalase level assay) models. The extract (100, 200 and 400 mg/kg) and silymarin (100 mg/kg) produced a significant ($p < 0.05$) dose-dependent increase in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphate levels in serum of treated rats, when compared with the negative control group. The extract (25 – 400 µg/ml concentration) produced a concentration-dependent increase in antioxidant activity in 2, 2-diphenyl-1-picrylhydrazine (DPPH) photometric assay. The IC₅₀ of the extract in DPPH photometric assay was 50 µg/ml concentrations. The extract and silymarin showed a significant ($p < 0.05$) dose-dependent increase in catalase level in treated rats, when compared with the negative control group. Also, the extract (400 mg/kg) and silymarin (100 mg/kg) produced a significant ($p < 0.05$) decrease in malondialdehyde level in treated rats, when compared with the negative control group. This study demonstrates that *C. sieberiana* leaves has a potent hepatoprotective and antioxidant activities. It justified the use of *C. sieberiana* leaves in the of liver injury related disease in folk medicine.

Keywords: *Cassia sieberiana*, carbon tetrachloride, catalase, malondialdehyde, hepatoprotective activity, silymarin

1. Introduction

The liver plays important metabolic, detoxification, and secretory roles in the body. Liver disease is associated with distortion of these metabolic functions [1]. Thus, liver diseases remain one of

the serious public health problems and its disorders are numerous with no effective treatment. Every year about 20,000 deaths are recorded due to liver disorders worldwide [2]. Despite considerable progress in the treatment of liver diseases by oral hepatoprotective agents, search for newer drugs continues because the existing synthetic drugs have several limitations [3-5]. So, the search for new medicines of plant origin is still ongoing due to the fact that liver performs many vital functions in the human body and damage of liver causes unbearable problems [6, 7].

Cassia sieberiana DC belongs to the family Fabaceae. It is called “drumstick” in English and its indigenous names in Nigeria include “marga” in hausa, “margaje” in Fulani, “kiskatigrai” in kanuri and “ifo” or “aridantooro.” in yoruba. It grows up to 10 – 20 m high with drooping branches and bright yellow flowers [8]. The fruit (pods) is cylindrical, smooth, 40 - 60 cm long and about 1.5 cm in diameter; indehiscent and dark brown. The plant is an open savannah tree found in drier areas of forest and thickets. The plant is widely distributed in the southern sahel and sudan savanna from Senegal to Cameroun, as far as Sudan and the Republic of Congo [9, 10]. It is also found in most parts of Nigeria [8]. Various parts of the plants are used for the treatment of fever, jaundice, stomach ache, gonorrhea, piles and ulcers in traditional medicine [8]. The extract from various parts of the plant have been shown to possess some pharmacological activities like; antioxidant, anti-ulcer, antidiabetic, laxative, wound healing and anti malarial [11-13]. The present study was aimed at investigating the hepatoprotective effect of methanolic extract of *Cassia sieberiana* (CSE) leaves in carbon tetrachloride-induced hepatotoxicity in rats.

2. Material and Methods

2.1. Collection and identification of plant material

Fresh leaves of *Cassia sieberiana* were collected in March, 2013 from Nsukka Enugu state, Nigeria and identified by Mr A.O. Ozioko, a Taxonomist at Bioresource Development and Conservation Programme (BDCP), Enugu state, Nigeria. A voucher specimen catalogued MOUAAU/VPP/2013/11 was deposited in the departmental herbarium for reference purposes.

2.2. Preparation of the plant extract

Dried and pulverized leaves of *Cassia sieberiana* (200 g) were extracted by cold maceration method for 48 hours at room temperature using 80% methanol in a Winchester bottle. Filtration was done using Whatmann No. 1 filter papers and the filtrate was concentrated in a hot air oven at 40 °C to give 19 g residue. The extract was stored in a refrigerator at 4 °C throughout the duration of this study.

63 **2.3. Experimental animals**

64 Thirty five male Albino Wistar rats (120-140 g) obtained from the laboratory animal unit of the
65 Department Of Veterinary Physiology, Pharmacology, Biochemistry, Animal health and
66 production; Michael Okpara University Agriculture, Umudike, was used for this study. They were
67 housed in aluminum cage at 5 rats per cage and were fed *ad libitum* with standard commercial
68 pelleted feed (Vital feed[®], Nigeria) with free access to clean drinking water. They were kept at
69 normal environmental temperature and natural light/darkness daily cycle. They were maintained
70 in accordance with the recommendations of the *Guide for the care and use of laboratory animals*
71 [14]. They were allowed two weeks to acclimatize before the commencement of the experiment.
72 The animal experiment protocol was approved by the Michael Okpara University of Agriculture
73 animal ethics committee.

75 **2.4. EXPERIMENTAL PROCEDURES**

76 **2.4.1. Phytochemical spot test**

77 The CSE was tested for the presence of alkaloids, flavonoids, tannins, glycosides, saponins,
78 terpenes/sterols, carbohydrates, and starch using the standard procedures [15].

79 **2.4.2. Oral acute toxicity study**

80 The oral acute toxicity test of methanolic extract of *Cassia sieberiana* was determined according
81 to the OECD guideline no. 425 (acute oral toxicity – Up-and-Down-procedure). Briefly, two
82 groups of five rats each were dosed orally with 1000 and 2000 mg/kg of CSE, respectively and
83 were observed for 48 h for signs of toxicity and death [16].

84 **2.4.3. Effects of *Cassia sieberiana* extract on carbon tetrachloride (CCl₄)-Induced** 85 **Hepatotoxicity Rats**

86 Twenty five male albino rats were randomly divided into five groups (I-V) of 5 rats each. Group I
87 (negative control) received 10 ml/kg of distilled water, group II (positive control) received
88 silymarin 100 mg/kg, while groups III – V received CSE at the doses of 100, 200 and 400 mg/kg,
89 respectively. All the animals were dosed orally once daily for 5 consecutive days. Twenty four
90 hours after the last treatment (day 6), 20% CCl₄ in liquid paraffin was administered
91 intraperitoneally to each rat at the dose of 2 ml/kg. After 24 h of CCl₄ treatment, rats were
92 anaesthetized with chloroform and blood was collected through direct cardiac puncture. Serum
93 was separated by centrifugation at 2000 rpm for 10 min and aspirated into sterile plain sample
94 bottles. The rats were later euthanized by cervical dislocation and the liver was dissected out
95 immediately for preparation of liver homogenate.

2.4.4. Serum biochemical analysis

Assay for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were done by the method described by Reitman and Frankel [17] and serum level of alkaline phosphatase was measured by the method of Klein et al. [18] using Randox test kits. The serum total protein and albumin content was assayed using standard diagnostic kit (Randox kit, Randox Laboratories, U.K.).

2.4.5. Determination of the lipid peroxidation (LPO) using liver homogenate

The level of thiobarbituric acid reactive substance (TBARS), a commonly used marker of lipid peroxidation and malondialdehyde (MDA) production was measured in liver homogenate by modified method as described by Draper and Hadley [19]. The liver homogenate (50 μL) was deproteinized by adding 1 mL of 14% trichloroacetic acid and 1 mL of 0.6% thiobarbituric acid. The mixture was heated in a water bath at 100 °C for 30 min to complete the reaction and then cooled on ice for 5 min. After centrifugation at 2000 rpm for 10 min, the absorbance of the colored product (TBARS) was measured at 535 nm with a UV spectrophotometer. The concentration of TBARS was calculated using the molar extinction coefficient of malondialdehyde ($1.56 \times 10^5 \text{ mol/L/cm}$) using the formula, $A = \Sigma CL$, where A = absorbance, Σ = molar coefficient, C = concentration, and L = path length. The results were expressed in nmol/mg of protein.

2.4.6. Estimation of the effects of CSE on catalase activity in serum

The catalase activity in serum was determined using the modified method as described by Aebi [20] and Atawodi [21]. Briefly, the method is as follows: serum (10 μL) was added to test tube containing 2.80 mL of 50 mM potassium phosphate buffer (pH 7.0). The reaction was initiated by adding 0.1mL of fresh 30 mM hydrogen peroxide and the decomposition rate of hydrogen peroxide was measured at 240 nm for 5 min on a spectrophotometer. A molar extinction coefficient of $0.041 \text{ mM}^{-1}\text{cm}^{-1}$ was used to calculate catalase activity. The results were expressed in $\mu\text{mol/mg}$ of protein.

2.4.7. Determination of *in vitro* antioxidant activities CSE using 2, 2-diphenyl-1-picrylhydrazyl (DPPH) photometric Assay

The free radical scavenging activity of the extract was analyzed by the DPPH Assay [22] using spectrophotometer. The test extract (2 ml) at different concentrations (25, 50, 100, 200 and 400 $\mu\text{g/ml}$) each were mixed with 0.5 mM DPPH (in 1 ml of methanol) in a cuvette. The absorbance at 517 nm was taken after 30 minutes of incubation in the dark at room temperature. The

concentrations were prepared in triplicates and the percentage antioxidant activity calculated as follows.

$$\% \text{ antioxidant activity (AA)} = 100 - \left[\frac{(\text{absorbance of sample} - \text{absorbance of blank}) \times 100}{\text{absorbance of control}} \right]$$

One mililiter of methanol plus 2.0 ml of the extract was used as the blank while 1.0 ml of the 0.5 mM DPPH solution plus 2.0 ml of methanol was used as the negative control. Ascorbic acid (vitamin C) was used as reference standard [23].

2.5. Statistical analysis

Data obtained were presented as mean $\pm$ SEM and analyzed using one-way analysis of variance (ANOVA). The variant mean were separated by least significant difference (LSD) of the different groups. Significance was accepted at the level of $p < 0.05$.

3. RESULT

3.1. Preparation of the extract

The weight of CSE recovered was 19 g, and the percentage yield was 9.5 % w/w dry matter. The extract was dark green in color and pasty in consistency.

3.2. Phytochemical spot test

The phytochemical spot test showed that CSE contained saponins, tannins, terpenes/sterols, glycosides, alkaloids and flavonoids.

3.3. Oral acute toxicity test

The oral administration of the CSE was well tolerated in all doses (1000–2000 mg/kg) as no death or clinical signs of toxicity were observed throughout the period of observation.

3.4. Effects of CSE on the liver function markers of carbon tetrachloride treated rats

The effects of CSE on the serum ALT, AST and ALP activities of carbon tetrachloride treated rats is presented in Table 1. The extract (100, 200 and 400 mg/kg) and silymarin (100 mg/kg) significantly ($p < 0.05$) reduced the activities of ALT, AST and ALP in the serum of treated rats in a dose-dependent manner, when compared with the negative control rats. Also, the extract (100, 200 and 400 mg/kg) and silymarin (100 mg/kg) produced no significant ($p > 0.05$) difference on the serum albumin and total protein levels in the treated rats when compared with the negative control rats.

Table 1: The effects of CSE on the liver function markers of carbon tetrachloride treated rats

Group	ALT (U/L)	AST (U/L)	ALP (U/L)	Total protein g/dl	Albumin g/dl
Distilled water 10 ml/kg	415.00 ± 5.00	250.50 ± 3.50	129.51 ± 1.76	6.90 ± 0.02	3.41 ± 0.05
Silymarin 100 mg/kg	224.50 ± 10.50*	135.00 ± 8.00*	64.01 ± 9.99*	4.47 ± 1.59	2.17 ± 0.79
CSE 100 mg/kg	347.67 ± 4.97*	203.33 ± 6.01*	64.53 ± 6.02*	4.85 ± 0.08	2.38 ± 0.84
CSE 200 mg/kg	316.67 ± 2.73*	175.00 ± 2.89*	62.60 ± 7.06*	4.51 ± 0.22	3.05 ± 0.09
CSE 400 mg/kg	278.00 ± 3.79*	159.67 ± 1.76*	60.17 ± 5.46*	4.76 ± 0.18	2.34 ± 0.28

*P < 0.05 when compared to the negative control

3.5. *In vivo* antioxidant effect of CSE on carbon tetrachloride treated rats

The *In vivo* antioxidant effect of CSE on carbon tetrachloride treated rats is presented on Table 2. All doses of the extract (100, 200 and 400 mg/kg) and silymarin (100 mg/kg) produced a dose-dependent reduction in the levels of malondialdehyde in liver homogenate of the treated rats. The malondialdehyde levels of the groups treated with CSE (400 mg/kg) and Silymarin (100 mg/kg) was significantly ($p < 0.05$) lower when compared with the negative control group. Also, the extract (100, 200 and 400 mg/kg) and silymarin (100 mg/kg) caused a significant ($p < 0.05$) dose-dependent increase in the serum catalase level in treated rats, when compared with the negative control rats.

Table 2: *In vivo* antioxidant effect of CSE on carbon tetrachloride treated rats

group	MDA (nmol/mg protein)	CATALASE (μmol/mg protein)
Distilled water 10 ml/kg	0.60 ± 0.14	1.07 ± 0.29
Silymarin 100 mg/kg	0.25 ± 0.02*	3.49 ± 0.19*
CSE 100 mg/kg	0.47 ± 0.08	1.23 ± 0.18

CSE 200 mg/kg	0.39 ± 0.02	2.20 ± 0.54*
CSE 400 mg/kg	0.27 ± 0.10*	3.38 ± 0.10*

*P < 0.05 when compared to the negative control

3.6. *In vitro* antioxidant activity of CSE using DPPH photometric assay

The *in vitro* antioxidant activity of CSE using DPPH photometric assay is presented in Figure 1. The extract produced concentration-dependent increase in the DPPH radical scavenging activity. The extract at 200 and 400 µg/ml concentration produced an effect that is comparable to the effect of ascorbic acid. The optimum effect of the extract was produced at 400 µg/ml concentration.




Figure 1: The *in vitro* antioxidant activity of CSE using DPPH photometric assay

4. Discussion

192 The hepatoprotective effect of the methanolic extract of *C. sieberiana* was studied using carbon
193 tetrachloride-induced hepatotoxicity. The antioxidant activity was studied using both in vivo (MDA
194 and catalase) and in vitro (DPPH radical scavenging) models.

195 The extraction of the *C. sieberiana* leaves for 48 h using cold maceration method yielded 9.5%
196 w/w of dark green and pasty extract. The phytochemical spot test of the CSE showed the presence
197 of saponins, alkaloids, flavonoids, terpene/sterol, glycosides and tannins. The hepatoprotective
198 action of the extract may be due to the presence of one or more of the phytochemical constituents
199 [24].

200 Oral acute toxicity test showed that the extract is well tolerated as no mortality or any clinical
201 signs were observed even at the highest administered dose of 2000 mg/kg used in this study [16,
202 25, 26].

203 Hepatotoxicity was induced by single intraperitoneal injection of 20% CCl₄ in liquid paraffin at
204 the dose of 2 ml/kg. Carbon tetrachloride-induced liver toxicity is a commonly used model for the
205 screening of hepatoprotective drugs [27]. The hepatotoxic effect of CCl₄ is mediated by its active
206 metabolite, trichloromethyl radical [28, 29]. The trichloromethyl radical covalently bind to
207 macromolecules and induce peroxidative degradation of the membrane lipids of endoplasmic
208 reticulum rich in poly unsaturated fatty acids [30]. The lipid peroxidation gives rise to the
209 generation of malondialdehyde (MDA), which causes damage to biomembranes. The membrane
210 damage leads to the elevation in levels of the cytosolic enzymes in serum [31]. In this work, the
211 induction of hepatotoxicity was evidenced by the increased serum levels of AST, ALT, ALP and
212 increased level of MDA in the liver homogenate of the negative control group of rats.

213 The pretreatment of the rats with CSE (100, 200 and 400 mg/kg) and silymarin (100 mg/kg)
214 before the induction of hepatotoxicity caused a significant ($p < 0.05$) reduction in the serum level of
215 AST, ALT and ALP in the treated rats when compared with the negative control group. This is an
216 indication that CSE may caused plasma membrane stabilization as well as repair of hepatic tissue
217 damage caused by CCl₄. This is in agreement with the report of other previous workers; that the
218 serum level of transferase and phosphatase return to normal with the healing of hepatic
219 parenchyma and regeneration of hepatocytes [30, 32, 33].

220 There was no significant difference ($P > 0.05$) in the serum level of total protein and albumin of
221 both the treated and control group and this may be attributed to the duration of the study [34].

The *in vitro* free radical scavenging activity of CSE was determined using DPPH photometric assay. The use of DPPH photometric assay model for screening of free radical scavenging activities of chemicals is well documented [33, 35]. The CSE produced a concentration-dependent increase in the free radical scavenging activity. The scavenging of DPPH radical is related to the inhibition of lipid peroxidation [36].

The lipid peroxidation was assayed by the measurement of the level of MDA in the liver homogenate. The treatment of the rats with CCl₄ caused an increased level of MDA in the liver homogenate as seen in Table 2. The pretreatment with silymarin and CSE produced a reduction in the MDA level which suggests that the extract may have inhibited the reductive dehalogenation of CCl₄ to trichloromethyl radical, catalysed by cytochrome P₄₅₀ in the liver cell endoplasmic reticulum. The trichloromethyl radical react rapidly, attacking microsomal lipids leading to its peroxidation and also covalently binds to microsomal lipids and proteins ultimately initiating a site of secondary biochemical processes which are the main cause of CCl₄ hepatotoxicity [30, 37].

The reduced catalase level observed in the negative control is due to increased reactive oxygen species (ROS) occasioned by the CCl₄ treatment [31]. The pretreatment of the rats with silymarin (100 mg/kg) and CSE (100, 200 and 400 mg/kg) increased the level of catalase in both the silymarin and CSE treated groups when compared with the negative control group. This may be due to the inhibition of the metabolic processes that would have lead to the generation of trichloromethyl radicals and other ROS from CCl₄ and subsequent exhaustion of the catalase [31]. Catalase catalyzes the conversion of hydrogen peroxide to water [38].

The results obtained from the antioxidant evaluation suggest that the possible mechanism of the hepatoprotective activity of *C. sieberiana* may be through the antioxidant activity. This is supported by the presence of flavonoids, saponins, tannin and terpenoids, which have been shown to possess antioxidant and hepatoprotective activities [30, 39].

In conclusion the results of this work demonstrate that *C. sieberiana* extract has a potent hepatoprotective action in carbon tetrachloride-induced liver damage in rats. This may be due to its antioxidant and free radical scavenging properties or may be as result of the presence of some phytochemicals. Further investigation is recommended to isolate the active principle and determine its mechanism of action.

253 Reference

- 254 [1] P. L. Wolf, "Biochemical diagnosis of liver disease," *Indian Journal of Clinical Biochemistry*,
255 vol.14, pp. 59–90, 1999.
- 256 [2] B. Banothu, P. Kusuma, R. Alli, T. Gorre, G. S. Rani, "Hepatoprotective studies of
257 *mussaenda raiateensis* extracts on carbon tetrachloride induced hepatotoxicity in rats,"
258 *International Journal of Pharmaceutical Biology*, vol. 1, no. 1, pp. 25-29, 2011.
- 259 [3] U. Latha, M. G. Rajesh, M. S. Latha, "Hepatoprotective effect of an ayurvedic medicine,"
260 *Indian Drugs*, vol. 36, pp. 470–473, 1999.
- 261 [4] N. Sriram, K. V. Kumar, S. Mantry, S. Sakthivel, P. S. Prasad, "Hepatoprotective effect of
262 *Malachra capitata* (L.) against carbon tetra chloride-induced hepatotoxicity in wistar albino rats,"
263 *International Journal of Pharmacy Review & Research*, vol 2, no. 2, pp. 106-110, 2012.
- 264 [5] S. Venkateswaran, L. Pari, P. Viswanathan, V. P. Menon, "Protective effect of Livex; a
265 herbal formulation against erythromycin estolate induced hepatotoxicity in rats," *Journal of*
266 *Ethnopharmacology*, vol. 57, no. 3, pp. 161–167, 1997.
- 267
- 268 [6] S. Lupper, "A review of plants used in treatment of liver disease, a part two," *Alternative*
269 *Medicine Review*, vol. 4, pp. 179–189, 1999.
- 270 [7] S. K. Mitra, M. V. Venkataranganna, R. Sundaram, and S. Gopumadhavan, "Protective effect
271 of HD-03, a herbal formulation, against various hepatotoxic agents in rats," *Journal of*
272 *Ethnopharmacology*, vol. 63, pp. 181-186, 1998.
- 273 [8] I. Toma, Y. Karumi and M. A. Geidam, "Phytochemical screening and toxicity studies of the
274 aqueous extract of the pods pulp of *Cassia sieberiana* DC. (*Cassia Kotchiana* Oliv.)," *African*
275 *Journal of Pure and Applied Chemistry*, Vol. 3, no.2, pp. 026-030, 2009.
- 276 [9] S. Gledhill, *Tropical Trees*. Longman Publishers, London. pp. 85-87, 1991.
- 277 [10] A. Michael, *Trees, shrubs and lianas of West Africa dry zones*, Ciriad Magraf publisher
278 Netherlands. p. 214, 2004.
- 279 [11] Z. Aliyu, M. Yusha'u, and B. S. Aliyu, "Anti malarial activity of *Cassia sieberiana* leaf
280 extracts," *The Open Conference Proceedings Journal*, vol. 4, pp. 72-76, 2013.

- 281 [12] T. E. Ihedioha, V. U. Omoja and I. U. Asuzu, “Effects of methanolic stem bark extract of
282 *Cassia sieberiana* DC on fasting blood glucose and serum lipid profile of alloxan-induced diabetic
283 rats,” *Animal Research International*, vol. 11, no. 1, pp. 1871–1880, 2014.
- 284 [13] E. T. Nartey, M. Ofosuhene, W. Kudzi, and C. M. Agbale, “Antioxidant and gastric
285 cytoprotective prostaglandins properties of *Cassia sieberiana* roots bark extract as an anti-
286 ulcerogenic agent,” *Complementary and Alternative Medicine*, 12:65, 2012.
- 287 [14] DHHS, *Guide for the care and use of laboratory animals. Institute of Laboratory Animal*
288 *Resources Commission on Life Sciences*, National Research Council. National Academy,
289 Washington, D.C. 1985.
- 290 [15] G. E. Trease and W. C. Evans, *Pharmacognosy*, 15th edn. Saunders, London, pp 58–302,
291 2002.
- 292 [16] OECD, *Guidelines for the testing of chemicals, acute oral toxicity – up-and-down-*
293 *procedure*, no. 425, Adopted 3 October 2008.
- 294 [17] S. Reitman and S. Frankel, “Colourimetric method for the determination of serum
295 transaminases,” *American Journal of Clinical Pathology*, vol. 28, pp. 56-61, 1957.
- 296 [18] B. Klein, P. A. Read, and L. A. Babson, “Rapid method for quantitative determination of
297 serum alkaline phosphatase,” *Clinical Chemistry*, vol. 6, pp. 269-275, 1960.
- 298 [19] H. H. Draper and M. Hadley, “Malondialdehyde determination as index of lipid
299 peroxidation,” *Methods in Enzymology*, vol. 186, pp. 421-431, 1990.
- 300 [20] H. Aebi. *Catalase*. In: Bergmeyer HV, editor. *Method of enzymatic analysis*. Academic
301 Press, New York, pp 673-684, 1974.
- 302 [21] S. E. Atawodi, ‘Evaluation of the hypoglycaemic, hypolipidemic and antioxidant effects of
303 methanolic extract of “Ata-Ofa” polyherbal tea (A-polyherbal) in alloxan-induced diabetic rats,”
304 *Drug Invention Today*, vol. 3, pp. 270-276, 2011.
- 305 [22] L. L. Mensor, S. M. Fabio, G. L. Gilda, S. R. Alexandre, C. D. Tereza, S. C. Cintia et al.,
306 “Screening of Brazilian plant extracts for antioxidant activity by the use of DPPH free radical
307 method,” *Phytotherapy Research*, vol. 15, pp. 127–130, 2001.

- 308 [23] E. O. Iwalewa, I. O. Adewale, B. J. Aiwo, T. Arogundabe, A. Osinowo, O. M. Daniyan et
309 al., “Effects of *Harungana madagascariensis* stem bark extract on the antioxidant markers in
310 alloxan induced diabetic and carrageenan induced inflammatory disorders in rats,” *Journal of*
311 *Complementary and Integrative Medicine*, vol. 5, no. 1, pp. 1–18, 2008.
- 312 [24] G. Di Carlo, N. Mascolo, A. A. Izzo, and F. Capasso, “Flavonoids: old and new aspects of
313 a class of natural therapeutic drugs,” *Life Sciences*, vol. 65, pp. 337-342, 1999.
- 314 [25] E. K. Ayebe, H. F. Yapi, A. A. Edjeme et al., “*In vivo*, *in vitro* antioxidant activity
315 assessment & acute toxicity of aqueous extract of *Cola nitida* (Sterculiaceae),” *Asian Journal of*
316 *Biochemical and Pharmaceutical Research*, vol. 2, no. 4, pp. 144–155, 2012.
- 317 [26] I. I. MadubunyiI, S. O. Onoja, and I. U. Asuzu, “*In vitro* anti-oxidant and *in vivo* anti-
318 diabetic potentials of the methanol extract of *Ficus glumosa* Del (Moraceae) stem bark in alloxan-
319 induced diabetic mice,” *Comparative Clinical Pathology*, vol. 21, pp. 389–394, 2012.
- 320 [27] D. E. Johnson and C. Kroening, “Mechanism of early carbon tetrachloride toxicity in
321 cultured rat hepatocytes,” *Pharmacology and Toxicology*, vol. 83, pp. 231-39, 1998.
- 322 [28] K. A. Shenoy, S. N. Somayaji, and K. L. Bairyl, “Hepatoprotective effects of *Ginkgo biloba*
323 against carbon tetrachloride induced hepatic injury in rats,” *Indian Journal of Pharmacology*, vol.
324 33, pp. 260-266, 2001.
- 325 [29] S. P. Srivastava, N. O. Chen, and J. L. Holtzman, “The *in vitro* NADPH dependent
326 inhibition by CCl₄ of the ATP-dependent calcium uptake of hepatic microsomes from male rats.
327 Studies on the mechanism of inactivation of the hepatic microsomal calcium pump by the CCl₃
328 radical, *Journal Biological Chemistry*, vol. 265, pp. 8392-8399, 1990.
- 329 [30] M. Gupta, U. K. Mazumder, T. S. Kumar, P. Gomathi and R. S. Kumar, “Antioxidant and
330 hepatoprotective effects of *Bauhinia racemosa* against paracetamol and carbon tetrachloride
331 Induced Liver Damage in Rats,” *Iranian Journal of Pharmacology and Therapeutics*, vol. 3, pp.
332 12-20, 2004.
- 333 [31] X. W. Li, R. Zhu, B. Li, M. Zhou, Q. J. Sheng, Y. P. Yang, *et al.*, “Mechanism underlying
334 carbon tetrachloride-inhibited protein synthesis in liver,” *World Journal Gastroenterology*, vol.
335 16, no. 31, pp. 3950-3956, 2010.
- 336 [32] A. H. Banskota, Y. Tezuka, I. K. Adnyana, Q. Xiong, K. Hase, K. Q. Tran *et al.*,
337 “Hepatoprotective effect of *commbretum quadrangulare* and its constituents, *Biological and*
338 *Pharmaceutical Bulletin*, vol. 23, pp. 456-460, 2000.

- 339 [33] A. Jain, M. Soni, L. Deb, A. Jain, S. P. Rout, V. B Gupta *et al.*, “Antioxidant and
340 hepatoprotective activity of ethanolic and aqueous extracts of *Momordica dioica* Roxb. Leaves,”
341 *Journal of Ethnopharmacology*, vol. 115, pp. 61–66,2008.
- 342 [34] M. Ezeja, Y. Omeh, I. Ezeigbo and B. Eze, “Effect of *Magnifera indica* leaf extract on
343 paracetamol-induced hepatic toxicity in rats,” *European Journal of Medicinal Plants*, vol. 4, no.
344 10, pp. 1167-1177, 2014.
- 345 [35] S. O. Onoja and A. O. Anaga, “Evaluation of the antidiabetic and antioxidant potentials
346 of methanolic leaf extract of *Helianthus annuus* L. on alloxan-induced hyperglycemic rats”
347 *Comparative Clinical Pathology*, 2013; Epub ahead of print 8 Oct 2013. DOI:
348 10.1007/s00580-013-1824.3
- 349 [36] E. Rekka and P. N. Kourounakis, “Effect of hydroxyethyl rutenosides and related
350 compounds on lipid peroxidation and free radical scavenging activity-some structural aspects,”
351 *Journal of Pharmacy and Pharmacology*, vol. 43, pp. 486–491, 1991.
- 352 [37] Y. H. Wei, “Oxidative stress and mitochondrial DNA mutations in human aging,”
353 *Proceedings of the Society for Experimental Biology and Medicine*, vol. 217, pp. 53-63, 1998.
- 354 [38] Y. N. Omeh, S. O. Onoja, M. I. Ezeja, and P. O. Okwor, “Sub-acute antidiabetic and *in vivo*
355 antioxidant effects of methanolic extract of *Bridelia micrantha* (hochst baill) leaf on alloxan-
356 induced hyperglycaemic rats,” *Journal of Complementary and Integrative Medicine*, vol. 11, no.
357 2, pp. 99-105, 2014.
- 358 [39] F. V. DeFeudis, V. Papadopoulos, and K. Drieu, “Ginkgo biloba extracts and cancer: a
359 research area in its infancy,” *Fundamental and Clinical Pharmacology*, vol. 17, pp. 405-417,
360 2003.

361